Skip to content

PMI Guide PS Setting in Pressure Support-ventilated Patients

PMI Guide PS Setting in Pressure Support-ventilated Patients - Prospective Multicenter Clinical RCT

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05963737
Enrollment
60
Registered
2023-07-27
Start date
2023-08-01
Completion date
2025-12-31
Last updated
2025-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mechanical Ventilation

Keywords

pressure support ventilation, inspiratory effort, inspiratory muscle pressure index

Brief summary

Pressure support ventilation (PSV) is an assistant mechanical ventilation mode, that is widely implemented in mechanical ventilation treatment but there are no exact guidelines to guide PS setting. Traditional PS setting strategy (VT/PBW 6-8ml/kg and RR 20-30 breaths/min)has risks of excessive or insufficient assistance. Inspiratory muscle pressure index (PMI) is a noninvasive respiratory mechanical indicator and is available at the bedside. PMI was correlated with inspiratory effort and has the potential ability to predict low inspiratory effort and high inspiratory effort. The primary objective of this study is to investigate the clinical validity of a PMI-guided PS setting strategy. Specifically, the investigators aim to evaluate its impact on inspiratory effort as well as its potential for lung and diaphragm protection. Additionally, the investigators seek to assess the effect of this ventilation strategy on mechanical ventilation outcomes while evaluating the feasibility of our trial protocol.

Detailed description

Pressure support ventilation (PSV) is an assistant mechanical ventilation mode to provide synchronous inspiratory support for patients with spontaneous breathing and to efficiently reduce the workload imposed on the respiratory muscle. PSV is widely implemented in mechanical ventilation treatment but there are no exact guidelines to guide PS setting. Clinicians and respiratory therapists usually adjust ventilator parameters based on tidal volume/predicted body weight (VT/PBW, 6-8ml/kg) and current respiratory rate (RR, 20-30 breaths/min). This strategy has risks of excessive or insufficient assistance because the PS setting cannot be modulated dynamically based on the requirements of ventilated patients. Inspiratory muscle pressure index (Pmus index, PMI) is defined as the difference between plateau pressure (Pplat) and airway peak pressure (Ppeak) during end-inspiratory occlusion (EIO). PMI is a noninvasive respiratory mechanical indicator and is available at the bedside like airway occlusion pressure (P0.1) because holding operations were integrated into the majority ventilator. Several studies showed PMI was correlated with inspiratory effort. Our previous study showed PMI has the potential ability to predict low inspiratory effort and high inspiratory effort, and the optimal cut-off PMI value was approximately 0 cmH2O and 2 cmH2O. The primary objective of this study is to investigate the clinical validity of a PMI-guided PS setting strategy. Specifically, the investigators aim to evaluate its impact on inspiratory effort as well as its potential for lung and diaphragm protection. Additionally, the investigators seek to assess the effect of this ventilation strategy on mechanical ventilation outcomes while evaluating the feasibility of our trial protocol.

Interventions

PROCEDUREPS setting strategy in pressure-support ventilated patients

Use PMI guide PS setting in pressure-supported ventilated patients and keep PMI within the target range (0-2cmH2O).

Sponsors

Capital Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients under PSV * Predicted ventilated time of more than 48 hours.

Exclusion criteria

* Age less than 18 years old; * Known pregnancy; * BMI\>35kg/m2; * Brain-stem or cervical cord injury; * Known or clinically suspected elevated intracranial pressure (ICP\>18 mmHg); * Nervus phrenicus or diaphragm injury; * Broncho-pleural fistula; * Chronic obstructive pulmonary disease (COPD); * Pressure support ventilated time more than 48 hours before randomization.

Design outcomes

Primary

MeasureTime frameDescription
The proportion of conditions in the range of normal inspiratory effort per patientup to 48 hoursthe time from the start of PSV mode to the successful weaning of the ventilated patients

Secondary

MeasureTime frameDescription
Tracheostomy rateup to 28 daysthe proportion of all subjects who underwent tracheostomy
Reintubation rateup to 28 daysthe proportion of all subjects who underwent reintubation
Diaphragm thickness (Tdi)up to 28 daysusing the Tdi to estimate the change of diaphragm function and activity during PSV
Diaphragm thicken fraction (TFdi)up to 28 daysusing the TFdi to estimate the change of diaphragm function and activity during PSV
The duration of mechanical ventilationup to 28 daysthe time from the start of mechanical ventilaion to the successful weaning of the patients
inspiratory muscle pressure (Pmus)up to 28 daysmeasuring Pmus to estimate the patient's inspiratory effort during the whole pressure-support ventilated duration
esophageal pressure time product (PTPes)up to 28 daysmeasuring PTPes to estimate the patient's inspiratory effort during the whole pressure-support ventilated duration
number of participants with treatment-related adverse events as assessed by CTCAE v4.0up to 28 daystreatment-related adverse events including pneumothorax, circulatory instability, etc.
Diaphragm excursion (EXdi)up to 28 daysusing the EXdi to estimate the change of diaphragm function and activity during PSV

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026